ClinicalTrials.gg
TerminatedNCT02090283Updated Nov 4, 2019Results posted

Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

A Phase 2 interventional study of SD-101 dermal cream (6%) in Epidermolysis Bullosa, sponsored by Scioderm, Inc.. Terminated at 7 sites in United States. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2019-11-04.

Sponsored by Scioderm, Inc. (part of BioMarin Pharmaceutical) · Phase 2, Interventional, and Treatment

Why this study was terminated
The Sponsor voluntarily recalled SD-101 and terminated the study due to GMP deficiencies identified during an FDA inspection at the site of the manufacturer.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
6 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 42 studies in Epidermolysis Bullosa with a site in United States — 10 open to participants now, 13 under way, 3 of them phase 3. Epidermolysis Bullosa · United States.

Enrollment
7th of 37
42 · median 16
Started
2014
with 1 other
Phase 2
11 of 42
2 open now
Registered
9th of 42
by date
Lead sponsor
4 of 42
Scioderm, Inc.

Among the 42 studies in Epidermolysis Bullosa with a site in United States, this one is the 7th largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2014, is one of 11 in phase 2, and was the 9th registered.

Epidermolysis Bullosa

86 studies on the registry are indexed under Epidermolysis Bullosa; 17 are open to participants now.

Browse Epidermolysis Bullosa studies →

Open to participants now

10 of the 42 studies in Epidermolysis Bullosa with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Epidermolysis Bullosa studies recruiting now, 9 (82%) set no upper age limit and 2 (18%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.

This study: 6 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Epidermolysis Bullosa with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study was to assess the continued safety of topical use of SD-101 cream (6%) in participants with Epidermolysis Bullosa (EB).

Funding Source: FDA Office of Orphan Products Development

Read the detailed description

This was an open-label extension study to assess the continued safety of topically applied SD-101 dermal cream (6%) in participants with Simplex, Recessive Dystrophic, and Junctional non-Herlitz EB.

SD-101 dermal cream (6%) was applied topically, once a day to the entire body for the duration of the study. Participants who successfully completed the entire SD-003 study (NCT02014376) had the option to roll over into the SD-004 study (NCT02090283). The baseline visit occurred at the final visit date for the SD-003 study. The body surface area (BSA) coverage of blisters and lesions assessment made at the final SD-003 study visit were used as the baseline information at the baseline visit for the SD-004 study. Participants returned to the study site for the following 13 visits (36 months) to have BSA assessed. BSA was assessed at all subsequent scheduled study center visits. Scheduled study center visits occurred every 6 months after Month 36 (Month 42, 48, and so on). After completion of Month 36, the next participant visit (Month 39) was a phone call from the site to the participant. Telephone visits occurred every 6 months thereafter (Month 45, 51, and so on) and included assessment of adverse events and concomitant medications only. For female participants of childbearing potential, a urine pregnancy test was performed at Month 6 and every 6 months up to and including the final study visit.

03

Conditions studied

  • Epidermolysis Bullosa

Browse trials for

Keywords

  • Amicus Therapeutics
  • Scioderm, Inc.
  • Recessive Dystrophic
  • Junctional non-Herlitz
  • Epidermolysis Bullosa
  • Simplex
  • SD-101 6%
  • SD-101-6.0
  • Allantoin 6%
  • Zorblisa
04

Who can participate

Ages eligible
6 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • form signed by the participant or participant's legal representative; if the participant is under the age of 18 but capable of providing assent, signed assent from the participant.
  • Participant (or caretaker) must be willing to comply with all protocol requirements.
  • Participant must have successfully completed the SD-003 study.

Exclusion criteria

Exclusion Criteria:

  • Participants who do not meet the inclusion criteria.
  • Pregnancy or breastfeeding during the study. A urine pregnancy test will be performed at the final visit for SD-003 for female participants of .
  • Females of childbearing potential who are not abstinent and not practicing a medically acceptable method of .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    SD-101 Dermal Cream (6%)

    All participants applied SD-101 dermal cream topically, once a day, to the entire body for the duration of the study.

    Drug: SD-101 dermal cream (6%)

Interventions

  • SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.

    Also known as: SD-101, SD-101-6.0, Zorblisa

06

What researchers measure

Primary outcomes

  1. Number Of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Treatment-emergent adverse events were defined as adverse events that started or worsened on or after baseline visit, which occurred at the final visit date for the SD-003 study. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: From baseline to 30 days after last application of study drug (up to a maximum of 54 months)

Secondary outcomes

  1. Change From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin At Month 24

    Lesional skin was defined as areas that contained any of the following: blisters, erosions, ulcerations, scabbing, bullae, or eschars, as well as areas that were weeping, sloughing, oozing, crusted, or denuded. The percentage, ranging from 0% to 100%, of affected body surface area (BSA) was recorded for each defined body region (that is, head/neck, upper limbs, trunk \[includes groin\], and lower limbs), multiplied by the weighting factor, and then summed for all body regions to calculate the BSAI. The BSA for lesional skin was to be assessed by the same study physician on each visit for a particular participant. The mean change from baseline (final visit from the SD-003 study) in BSAI was assessed every 3 months. Only participants with data available for analysis at the specified time point are presented.

    Time frame: Baseline, Month 24

07

Results

Posted Nov 4, 2019
Limitations and caveats
Results are presented for all participants who received SD-101 before the early termination of the study on 4 June 2018. The maximum study duration completed by at least 1 participant was 54 months.

Participant flow

42 participants with epidermolysis bullosa (EB) were enrolled in this open-label, multi-center extension study. All enrolled participants had previously completed Study SD-003 (NCT02014376).

Participant flow — Overall Study
MilestonePlacebo to SD-101-6.0SD-101-3.0 to SD-101-6.0SD-101-6.0 to SD-101-6.0
Started171510
Received at least 1 dose of study drug171510
Completed000
Not completed171510
Withdrew: Withdrawal by subject666
Withdrew: Sponsor terminated study661
Withdrew: Lost to follow-up223
Withdrew: Adverse event110
Withdrew: Protocol violation200

Outcome measures

PrimaryNumber Of Participants With Treatment-Emergent Adverse Events (TEAEs)

Treatment-emergent adverse events were defined as adverse events that started or worsened on or after baseline visit, which occurred at the final visit date for the SD-003 study. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
From baseline to 30 days after last application of study drug (up to a maximum of 54 months)
Reported as:
Count of participants · Participants
Number Of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPlacebo to SD-101-6.0SD-101-3.0 to SD-101-6.0SD-101-6.0 to SD-101-6.0
Any TEAE13145
Any TEAE Related to Study Drug110
Any Fatal TEAE000
Serious TEAE420
Any TEAE Leading to Discontinuation110
SecondaryChange From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin At Month 24

Lesional skin was defined as areas that contained any of the following: blisters, erosions, ulcerations, scabbing, bullae, or eschars, as well as areas that were weeping, sloughing, oozing, crusted, or denuded. The percentage, ranging from 0% to 100%, of affected body surface area (BSA) was recorded for each defined body region (that is, head/neck, upper limbs, trunk \[includes groin\], and lower limbs), multiplied by the weighting factor, and then summed for all body regions to calculate the BSAI. The BSA for lesional skin was to be assessed by the same study physician on each visit for a particular participant. The mean change from baseline (final visit from the SD-003 study) in BSAI was assessed every 3 months. Only participants with data available for analysis at the specified time point are presented.

Time frame:
Baseline, Month 24
Reported as:
Mean · percentage of BSAI
Change From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin At Month 24
percentage of BSAIPlacebo to SD-101-6.0SD-101-3.0 to SD-101-6.0SD-101-6.0 to SD-101-6.0
Change From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin At Month 241.99 ± 6.728-3.73 ± 6.152-9.50 ± 21.248

Adverse events

Collected over From baseline (Day 0) to 30 days after last application of study drug (up to a maximum of 54 months).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo to SD-101-6.00/17 (0%)4/17 (23.5%)13/17 (76.5%)
SD-101-3.0 to SD-101-6.00/15 (0%)2/15 (13.3%)13/15 (86.7%)
SD-101-6.0 to SD-101-6.00/10 (0%)0/10 (0%)5/10 (50%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventPlacebo to SD-101-6.0SD-101-3.0 to SD-101-6.0SD-101-6.0 to SD-101-6.0
Benign breast neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/171/150/10
Major depressionPsychiatric disorders0/171/150/10
Suicide attemptPsychiatric disorders0/171/150/10
Respiratory arrestRespiratory, thoracic and mediastinal disorders0/171/150/10
AnaemiaBlood and lymphatic system disorders1/170/150/10
LymphadenopathyBlood and lymphatic system disorders1/170/150/10
BradycardiaCardiac disorders1/170/150/10
CyanosisCardiac disorders1/170/150/10
Abdominal painGastrointestinal disorders1/170/150/10
Gastrointestinal haemorrhageGastrointestinal disorders1/170/150/10
Most frequent other events
Showing 10 of 84
Most frequent other events
EventPlacebo to SD-101-6.0SD-101-3.0 to SD-101-6.0SD-101-6.0 to SD-101-6.0
PyrexiaGeneral disorders1/174/150/10
Skin infectionInfections and infestations4/172/150/10
PruritusSkin and subcutaneous tissue disorders2/173/150/10
AnaemiaBlood and lymphatic system disorders3/170/150/10
ConjunctivitisEye disorders0/172/150/10
PainGeneral disorders0/172/150/10
Ear infectionInfections and infestations2/172/150/10
InfluenzaInfections and infestations1/172/150/10
Nasal congestionRespiratory, thoracic and mediastinal disorders0/172/151/10
Upper respiratory tract infectionInfections and infestations2/170/151/10

Baseline characteristics

Safety: All participants who successfully rolled over into the SD-004 study from the SD-003 study and applied/were administered at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Placebo to SD-101-6.0SD-101-3.0 to SD-101-6.0SD-101-6.0 to SD-101-6.0Total
Mean11.29 ± 10.38515.70 ± 15.9288.10 ± 4.79512.11 ± 11.945
Sex: Female, Male
Sex: Female, Male(Participants)Placebo to SD-101-6.0SD-101-3.0 to SD-101-6.0SD-101-6.0 to SD-101-6.0Total
Female58518
Male127524
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo to SD-101-6.0SD-101-3.0 to SD-101-6.0SD-101-6.0 to SD-101-6.0Total
Hispanic or Latino56314
Not Hispanic or Latino129728
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo to SD-101-6.0SD-101-3.0 to SD-101-6.0SD-101-6.0 to SD-101-6.0Total
Race — White/Caucasian1615738
Race — Black or African-American1023
Race — Asian0011
EB Subtype
EB Subtype(Participants)Placebo to SD-101-6.0SD-101-3.0 to SD-101-6.0SD-101-6.0 to SD-101-6.0Total
Simplex44311
Recessive Dystrophic108624
Junctional non-Herlitz3317
08

Study locations

7 sites
  • Palo Alto, California 94304, United States
  • Chicago, Illinois 60611, United States
  • Saint Louis, Missouri 63110, United States
  • Hackensack, New Jersey 07601, United States
  • Chapel Hill, North Carolina 27516, United States
  • San Antonio, Texas 78218, United States
  • Seattle, Washington 98105, United States
09

References and documents

Publications

  • Paller A., Browning J., Aslam R., et al. Efficacy and Safety Results From a 24-Month, Open-Label Extension of a Phase 2b Dose-Ranging Study of SD-101 Cream in Patients With Epidermolysis Bullosa. Abstract presented at European Academy of Dermatology and Venereology, 26th Congress, Geneva, Switzerland, September 13-17, 2017.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2014 to primary completion in Sep 2018, 53 months.

Results were first posted in Nov 2019, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2014
First posted
Mar 18, 2014
StartActual
Mar 26, 2014
Primary completionActual
Sep 14, 2018
CompletionActual
Sep 14, 2018
Results first posted
Nov 4, 2019
Last update
Nov 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02090283
Lead sponsor
Scioderm, Inc.
Collaborators
Amicus Therapeutics, Food and Drug Administration (FDA)
Responsible party
Sponsor
First posted
Mar 18, 2014
Start date
Mar 26, 2014
Primary completion
Sep 14, 2018
Completion
Sep 14, 2018
Results posted
Nov 4, 2019
Last update
Nov 4, 2019

Study contacts

Medical Monitor
study director · Amicus Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nelitolimod

Start the discussion